MRNA +115%: Intismeran Phase 3 Win Validates mRNA Cancer Platform

Moderna stock more than doubled last week — up roughly 115% at its peak — after Merck and Moderna announced on August 19 that the Phase 3 INTerpath-001 trial of intismeran autogene (V940, formerly mRNA-4157) in combination with Keytruda (pembrolizumab) met its primary endpoint of recurrence-free survival (RFS) and the key secondary endpoint of distant metastasis-free survival (DMFS) in completely resected stage IIB-IV melanoma.

This is the first positive Phase 3 readout for an individualized neoantigen therapy (INT) and for an mRNA-based cancer therapy, period. It is also the first Phase 3 study to show a clinically meaningful improvement over Keytruda alone — the entrenched standard of care — in the adjuvant melanoma setting.

What the trial showed

INTerpath-001 enrolled 1,137 patients with completely resected stage IIB, IIC, III, or IV cutaneous melanoma and no prior systemic therapy. Patients were randomized 2:1 to intismeran (1 mg every three weeks for up to nine doses) plus Keytruda (400 mg every six weeks for up to nine cycles) versus Keytruda alone for roughly one year.

At a pre-specified interim analysis, the combination demonstrated statistically significant and clinically meaningful improvements in both RFS and DMFS. The companies did not disclose full hazard ratios in the topline release — full data is expected at an upcoming medical meeting — but the Phase 2b KEYNOTE-942 foundation, with five-year follow-up presented at ASCO 2026, showed a 49% reduction in the risk of recurrence or death (HR 0.51, 95% CI 0.294-0.887) and a 59% reduction in the risk of distant metastasis or death (HR 0.411, 95% CI 0.200-0.843). Four-year RFS in the Phase 2b was 72.4% versus 49.1% for Keytruda alone.

Analyst framing before the readout matters here. Citi said an RFS hazard ratio at or below 0.72 would be “positive” and at or below 0.65 a “clear win.” Jefferies put the meaningful range at 0.5 to 0.8. By those benchmarks, the topline language — “statistically significant and clinically meaningful” with the trial continuing to overall survival follow-up — was as good as investors could have reasonably expected without the actual HR.

Why this is bigger than melanoma

Melanoma is the proof-of-concept indication. The commercial prize is the platform. Intismeran is built from each patient’s own tumor mutational fingerprint — sequencing a resected tumor, selecting up to 34 neoantigen targets, and manufacturing a bespoke mRNA therapy in weeks. A validated Phase 3 signal means the personalized cancer vaccine thesis survives contact with registrational-scale evidence, and Moderna and Merck are running intismeran combinations across a slate of additional Phase 2 and 3 trials in other solid tumors.

For Moderna, this is existential. The stock entered the week near multi-year lows with the COVID franchise in decline, norovirus stuttering after the NOVA-301 interim miss, and the seasonal flu vaccine (mFLUSIVA, approved August 2026) carrying launch expectations the market discounted. A validated oncology platform changes the terminal-value math. Roughly 112,000 new melanoma cases will be diagnosed in the U.S. in 2026, and the majority of recurrences are metastatic rather than localized — exactly the patient population adjuvant therapy exists to protect.

For Merck, the calculus is defensive and offensive at once. Keytruda faces its patent cliff at the end of the decade, with biosimilar erosion beginning 2028-2029. Intismeran plus Keytruda in the adjuvant setting could extend franchise economics into the 2030s by making the combination the new standard of care before biosimilars arrive. The 50/50 U.S. profit share between the companies means Moderna captures half of what is, for Merck, partly a hedge.

What to watch

First, the full dataset. “Statistically significant and clinically meaningful” is topline language; the actual hazard ratio, confidence intervals, and subgroup performance determine whether regulators and payors move. Second, the regulatory filing. With Breakthrough Therapy designation already in hand, a BLA submission on INTerpath-001 is the next catalyst — watch for the acceptance and PDUFA date, which we will track on the FDA calendar. Third, overall survival. The trial continues, and an OS benefit is what converts an adjuvant approval into an entrenched standard.

The risk for anyone chasing the stock after a double is that platform value is already partly priced in. The right comparison is not what MRNA was worth last month — it is what a company with a validated personalized oncology platform, a 50/50 deal on a Keytruda-anchored franchise, and a stack of unconfirmed Phase 2/3 readouts ahead is worth. That debate will run for quarters. For background on how we evaluate readouts like this, see our guide to reading a clinical trial press release, the earlier breaking coverage of the readout, and our Modern platform economics analysis.

Source: Merck press release | Fierce Biotech